
    
      A multicentre, randomised, placebo-controlled, double-blind, 4-arm parallel-group, 2-week
      study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of
      GW642444H (100 administered once daily in the morning via DISKUSâ„¢ dry-powder inhaler)
      compared with SEREVENT (salmeterol) (50mcg administered twice daily via DISKUS dry-powder
      inhaler) and placebo in subjects with moderate COPD.
    
  